Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ConocoPhillips (COP) vs Inovio Pharmaceuticals Inc (INO) Price & Performance

ConocoPhillipsTrade
Inovio Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

ConocoPhillips vs Inovio Pharmaceuticals Inc — how do they compare? ConocoPhillips trades at $125.89 (market cap $147.80B), while Inovio Pharmaceuticals Inc trades at $0.77 (market cap $76.09M). The key difference: ConocoPhillips is far larger — about 1942.4× Inovio Pharmaceuticals Inc's market cap, and ConocoPhillips pays a 2.73% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

COPINO
Market Cap
$147.80B$76.09M
Sector
EnergyHealth
52-Week High
$133.80$2.87
52-Week Low
$85.66$0.66
Enterprise Value
$163.40B$47.10M
Dividend Yield
2.73%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ConocoPhillips

ConocoPhillips (COP) trades at $117.61, up 0.73% today, with a bullish technical signal from moving averages and a consensus analyst price target of $149.25. Recent Q2 2026 earnings beat expectations with EPS of $3.24 versus $2.90 estimated, driven by strong Permian Basin output and higher oil prices. The company reaffirmed its $7 billion free cash flow target by 2029 and completed a $1.7 billion asset sale ahead of schedule.

Outlook is positive due to robust operational performance and favorable oil market trends, but risks include commodity price volatility and CEO transition. The stock offers value with a P/E of 15.56 and a net income margin of 14.65%, supported by 74.51% analyst buy ratings.

Inovio Pharmaceuticals Inc

INO trades at $0.668, down 0.86% with bearish technical signals despite recent earnings beats. The company shows minimal revenue of $65,340 against substantial losses, with negative margins and cash flow challenges. Key catalyst is the FDA's October 2026 decision on INO-3107, while recent $20 million offering aims to fund operations.

High-risk biotech play with binary FDA outcome driving valuation. Analyst consensus is bullish (53% buy) with $3.25 price target, but fundamental weaknesses and litigation risks require caution. Success of INO-3107 is critical for turnaround, with current cash funding operations into early 2027.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ConocoPhillips

ConocoPhillips is a U.S.-based independent exploration and production firm. In 2021, it produced 1.0 million barrels per day of oil and natural gas liquids and 3.2 billion cubic feet per day of natural gas, primarily from Alaska and the Lower 48 in the United States and Norway in Europe and several countries in Asia-Pacific and the Middle East. Proven reserves at year-end 2021 were 6.1 billion barrels of oil equivalent.

Read more on COP

About Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Read more on INO